4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Mirxes Holding Company Limited (2629) operates in the Biotechnology industry and is headquartered in Singapore, Singapore with about 347 employees. Its market capitalization is roughly HK$4 billion. In the fiscal year ended 2024-12-31, 2629 reported $20M in revenue and ($92M) in net income.
Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China.
Interactive charts & full statements → Open the 2629 valuation workbench →
| Income statement | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Revenue | $20M | $24M | $18M |
| Gross Profit | $9M | $14M | $9M |
| Operating Income (EBIT) | ($67M) | ($54M) | ($48M) |
| Net Income | ($92M) | ($69M) | ($57M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Assets | $71M | $108M | $120M |
| Total Liabilities | $270M | $240M | $182M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2629 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms